

Munich Re Group

Quarterly Statement as at 30 September 2023

8 November 2023

Christoph Jurecka (CFO)



Quarterly Statement as at 30 September 2023

Agenda













O1 Munich Re

Consistently strong operating performance across all segments








Return on equity¹




Total technical result €m



Net financial result €m



Operating result €m



RI net result Q3 (9M): **€995**m (**€**2,950m)

Below-average major losses in P-C, TTR in L&H again above pro-rata guidance, Rol¹ of 2.2% (2.4%)

Property-casualty: Combined ratio: 82.0% (83.0%) – major loss ratio: 11.7% (12.5%) – reserve releases²: –5.1% (–5.0%) – net result: €644m (€1,982m)

Life and health: Total technical result: €440m (€1,084m) – net result: €351m (€968m)

ERGO net result Q3 (9M): €173m (€643m)

Good TTR in L&H Germany, P-C Germany with higher major losses, strong result in International, Rol¹ of 0.9% (1.4%)

Life and Health Germany: Total technical result: €276m (€819m) – net result: €52m (€165m)


Property-casualty Germany: Combined ratio: 88.2% (85.8%) –

net result: €31m (€260m)

International: Combined ratio: 87.9% (90.3%) – net result: €90m (€218m)

Capital position







€1,728m Insurance contracts

9M **-€1,407**m

€964m

Return on equity

Reinsurance **ERGO**


Q3 9M 16.5% **16.7**% 12.6% **15.4**% Solvency II ratio

271%


Investments



Investment portfolio¹



3-month reinvestment yield



Portfolio management in Q3

- Investment in corporate bonds and high interest rates support increase in reinvestment yield
- Expansion of alternative investments

Investment result



€m		Q3 2023	Return ¹	9M 2023	Return ¹	9M 2022	Return ¹
Regular income		1,797	3.3%	5,162	3.2%	4,718	2.7%
Write-ups/write-downs		-26	0.0%	-64	0.0%	-2,638	-1.5%
Change in expected credit loss (ECL)		-69	-0.1%	-95	-0.1%	0	0.0%
Disposal gains/losses		-196	-0.4%	-425	-0.3%	2,390	1.4%
Fair value change		-579	-1.1%	-1,114	-0.7%	-2,752	-1.6%
Other income/expenses		-168	-0.3%	-494	-0.3%	-452	-0.3%
Investment result		760	1.4%	2,969	1.8%	1,266	0.7%
Q3 2023	Fixed income	Equities	Other		9M 2023 Fixed income		Other
Write-ups/write-downs	0	Equities 0	-26	TIAG	0	Equities 0	-64
Disposal gains/losses	-198	0	2		-785	0	360
Fair value change	-252	-268	-60		-754	49	-409



02

ERGO

ERGO Life and Health Germany




Key messages



- Good total technical result in Q3, supported by a high contribution from health and travel business
- Net result in Q3 of €52m mainly due to life back book and health


Insurance revenue (gross)



 Increase in insurance revenues especially driven by short- and long-term health and travel

Total technical result






Q3 driven by:

- CSM release in line with expectations
- Strong contribution of €67m from PAA business in short-term health and travel

Contractual service margin (CSM)¹





- 9M: CSM release in life back book and health partially compensated for by profitable new business and operating changes
- CSM as of 30.6. elevated due to intra-year effect

ERGO Property-casualty Germany




Key messages




- Solid total technical result, despite higherthan-expected nat cat losses in Q3
- Net result in Q3 at €31m mainly impacted by low investment result including realisation of unrealised losses

Insurance revenue (gross)




Growth mainly driven by motor and liability

Total technical result €m



Combined ratio



- Good operating performance with total technical result in Q3 in line with expectations, despite higher expenses for nat cat losses
- Q1 to Q3: low acquisition costs due to seasonality in PAA business
- Q4: burden on technical result from significantly higher acquisition costs expected
- Discount effect:Q3 ~3.5pp, 9M ~3pp

ERGO International




Key messages



- Total technical result in Q3 supported by insurance revenue growth, favourable claims development and CSM release within expectations
- Net result in Q3 at €90m due to strong operating performance


Insurance revenue (gross)



 Increase mainly from Poland P-C (+€180m), Spain Health (+€84m) and Belgium Health (+€72m) and full consolidation of ERGO Thailand

Total technical result






- Strong CR in Q3 of 87.9% (114.8%):
 - Favourable development of basic loss and expense ratio
- Stable result from large losses, despite nat cat in Greece
- In Q3 ongoing good development in life/health from CSM release and experience adjustment (claims reserves) in Belgium Health

Contractual service margin (CSM)¹

Quarterly Statement as at 30 September 2023

€m



- Development in 9M mainly due to:
- profitable new business, ...
- ... overcompensated for by CSM release and operating changes

11



04

Reinsurance

Life and health reinsurance




Key messages



- Strong total technical result in Q3 above pro-rata guidance, full-year guidance already exceeded after 9 months
- Pleasing new business development, especially in North America

Insurance revenue (gross)




 Decline in Continental Europe and Asia, partly offset by growing revenue in North America and UK

Total technical result

€m

2023



03


2022

- Release of CSM and RA in line with expectations
- Positive impact from new business
- Growing result from insurancerelated financial instruments. including positive FX effects of €126m in Q3 (€7m in 9M)

Contractual service margin (CSM)¹

2022

2023



- Pleasing contribution from new business, exceeding release into earnings
- Decline vs. year-end 2022 caused by a shift from CSM to RA

13

Property-casualty reinsurance



Key messages



- Revenue growth of 3.6% vs. 9M 2022 despite FX headwinds
- Good combined ratio of 82.0% in Q3 supported by lower-than-expected major losses
- Normalised combined ratio at 85.5% in Q3 slightly better than guidance

Insurance revenue (gross)

€m

9M 2022

19,349

Foreign exchange

-571

Divestments/investments

0

Organic change


1,260

9M 2023


20,038

- Proportional business: new business and primary rate increases compensate for non-renewed shares
- XL business: increased prices in nat cat
- Global Specialty Insurance: substantial growth across all units


Total technical result €m



Combined ratio



- Q3 2023 combined ratio lower than Q3 2022, which had been impacted by Hurricane Ian (major losses 11.7% vs. 30.8%)
- Q3 2023 marked by Wildfire Maui and several severe weather events in Europe
- Impact from major losses, currencies and shape of yield curves contribute to discount benefit in combined ratio of ~10pp in Q3 (~9pp in 9M) ...
- ... offset by prudent reflection of claims uncertainty in basic losses
- Release of loss component of 1.1pp (Q3 2022: –2.9pp) benefits the CR



04

Outlook

Outlook 2023



Group

Insurance revenue (gross)

~ **€58**bn

Net result

~ **€4.5**bn (prev. ~ **€**4.0bn)

Return on investment

> 2.2%

ERGO

Insurance revenue (gross)

~ **€20**bn

(prev. ~ €19bn)

Net result

~ **€0.7**bn

Combined ratio P-C Germany

~ 89%

International

~ 90%

Reinsurance

Insurance revenue (gross)

~ **€38**bn

(prev. ~ €39bn)

Net result

~ **€3.8**bn

(prev. ~ €3.3bn)

Combined ratio Property-casualty

~ 85%

(prev. ~ 86%)

Total technical result Life and health

~ **€1.4**bn

(prev. ~ €1.0bn)

Disclaimer



This presentation contains forward-looking statements that are based on current assumptions and forecasts of the management of Munich Re. Known and unknown risks, uncertainties and other factors could lead to material differences between the forward-looking statements given here and the actual development, in particular of the results, financial situation and performance of our Group. Obvious fluctuations in the incidence of major losses in addition to the pronounced volatility of the capital markets and exchange rates – as well as the special features of IFRS accounting – make an accurate forecast of results impossible. The Group assumes no liability to update these forward-looking statements or to make them conform to future events or developments. Due to rounding, there may be minor deviations in summations and in the calculation of percentages in this presentation. Figures for FY 2022 are based on IFRS 17 and IAS 39 including overlay approach.